S
Stephan R. Targan
Researcher at Cedars-Sinai Medical Center
Publications - 577
Citations - 61849
Stephan R. Targan is an academic researcher from Cedars-Sinai Medical Center. The author has contributed to research in topics: Inflammatory bowel disease & Ulcerative colitis. The author has an hindex of 108, co-authored 545 publications receiving 58069 citations. Previous affiliations of Stephan R. Targan include University of Münster & Mount Sinai Hospital, Toronto.
Papers
More filters
Patent
Methods of predicting the need for surgery in crohn's disease
TL;DR: In this paper, the authors proposed methods of predicting susceptibility to a severe form of Crohn's disease in an individual by determining the presence or absence of one or more risk variants.
Journal ArticleDOI
Active target cell processes, possibly involving receptor-mediated endocytosis, are critical for expression of cytotoxicity by natural killer cell-derived cytolytic factor.
TL;DR: It was determined that NKCF did not cause a decrease in the rate of protein synthesis up to the time of cell death, suggesting that active target cell processes (possibly involving receptor-mediated endocytosis of NKCF) must occur for target cell lysis to be completed.
Journal ArticleDOI
Su1133 Influence of Biologic Agents on Short-Term Postoperative Complications in Patients With Crohn's Disease: A Prospective, Single-Surgeon Cohort Study
Cheryl C. Lau,Marla Dubinsky,Gil Y. Melmed,Eric A. Vasiliauskas,Dermot P.B. McGovern,Dror Berel,Zuri Murrell,Andrew Ippoliti,David Q. Shih,Manreet Kaur,Stephan R. Targan,Phillip Fleshner +11 more
Journal ArticleDOI
Strain-dependent differences in susceptibility of mice to experimental pyelonephritis.
Phyllis A. Guze,Linda M. Karavodin,Benjamin Bonavida,George M. Kalmanson,Kenji Ishida,Stephan R. Targan,Lucien B. Guze +6 more
Patent
Methods of predicting medically refractive ulcerative colitis (mr-uc) requiring colectomy
Jerome I. Rotter,Kent D. Taylor,Stephan R. Targan,Talin Haritunians,Dermot P.B. McGovern,Xiuqing Guo +5 more
TL;DR: In this paper, disclosed methods of predicting the development of medically refractory ulcerative colitis (MR-UC) in a patient are presented. But, they do not consider the treatment of MR-UC.